![EQS-PVR: Zalando SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution](https://aktienmedia.de/wp-content/uploads/2026/02/1771574824_Zalando-Aktie-News-02-ISIN-DE000ZAL1111-300x131.jpg "EQS-PVR: Zalando SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution")
Listen to the article
0:00
0:00
Kernaussagen
🌐 Translate Article
Translating...
📖 Read Along
💬 AI Assistant
🤖
Hi! I'm here to help you understand this article. Ask me anything about the content!
Valneva erwartet dann die Phase-III-Daten für den Borreliose-Impfstoff VLA15, den großen Hoffnungsträger, der mit Pfizer gemeinsam entwickelt wird. Ausreichende Liquidität für die weitere klinische Entwicklung ist vorhanden. Die Bewertung der Aktie dürfte direkt und weitgehend von den anstehenden Studienergebnissen abhängen.
Den vollständigen Artikel hier lesen
![EQS-PVR: Zalando SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution](https://aktienmedia.de/wp-content/uploads/2026/02/1771574824_Zalando-Aktie-News-02-ISIN-DE000ZAL1111-450x197.jpg "EQS-PVR: Zalando SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution")
6 Kommentare
I’ve been following this closely. Good to see the latest updates.
This is very helpful information. Appreciate the detailed analysis.
Great insights on Aktien-News. Thanks for sharing!
Interesting update on VALNEVA – Entscheidung im ersten Halbjahr. Looking forward to seeing how this develops.
Good point. Watching closely.
Solid analysis. Will be watching this space.